You just read:

Phase 3 QuANTUM-R Study Demonstrates Daiichi Sankyo's Quizartinib Significantly Prolongs Overall Survival as Single Agent Compared to Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations

News provided by

Daiichi Sankyo Company, Limited

18 Jun, 2018, 07:00 BST